Mar 31, 2022

Ultragenyx Q1 2022 Earnings Report

Ultragenyx reported first quarter results with a total revenue of $79.9 million and reaffirmed financial guidance for 2022.

Key Takeaways

Ultragenyx reported a total revenue of $79.9 million for the first quarter of 2022. The company reaffirmed its 2022 revenue guidance for Crysvita and Dojolvi.

Total revenue for the first quarter of 2022 was $79.9 million.

Crysvita revenue in Ultragenyx territories was $54.6 million.

Dojolvi product sales were $12.4 million.

The company reaffirmed 2022 Crysvita revenue guidance of $250 million to $260 million and Dojolvi revenue guidance of $55 million to $65 million.

Total Revenue
$79.9M
Previous year: $99.4M
-19.6%
EPS
-$2.19
Previous year: -$2.03
+7.9%
Total Operating Expenses
$217M
Previous year: $206M
+5.1%
Gross Profit
$79.9M
Cash and Equivalents
$814M
Previous year: $1.05B
-22.3%
Free Cash Flow
-$150M
Total Assets
$1.38B
Previous year: $1.6B
-13.4%

Ultragenyx

Ultragenyx

Ultragenyx Revenue by Segment

Forward Guidance

The company continues to expect 2022 revenue for Crysvita in Ultragenyx territories to be between $250 million and $260 million and Dojolvi revenue to be between $55 million and $65 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income